Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Exercise may stop joint pain in breast cancer patients on hormone pills

NCT ID NCT07295457

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 1 time

Summary

This study tests if starting a personalized exercise program early can prevent or reduce joint and muscle pain caused by aromatase inhibitors, a common hormone therapy for breast cancer. About 182 postmenopausal women with hormone-sensitive breast cancer will either receive the exercise program or usual care. The goal is to see if exercise helps women stay active, feel better, and stick with their cancer treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 182 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2026

Expected to finish

Jul 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Quantitative study: * Women aged 18 to 75 * Person with non-metastatic breast cancer * positive for at least one hormone receptor * Person treated with an Aromatase Inhibitor * Person with the following treatment regimen: Surgery - radiotherapy - aromatase inhibitor hormone therapy or surgery - chemotherapy (neoadjuvant or adjuvant) +/- targeted therapy - +/- radiotherapy - aromatase inhibitor hormone therapy. * Person affiliated to a social security scheme * Person having signed a free and informed consent Qualitative study: For patients : * Patient having given consent to participate in the APIS study * Patient agreeing to participate in the qualitative study (box checked on the APIS informed consent form) * Patient agreeing to the recording of the semi-directive interview For healthcare professionals : * Person practicing within the Saint-Étienne University Hospital and the Croix-Rousse University Hospital as a surgeon, oncologist, radiotherapist, sports medicine physician, APA instructor, physiotherapist, head nurse, care coordinator nurse, or advanced practice nurse * Persons working with patients treated with aromatase inhibitors for non-metastatic breast cancer * Person who has received individual information * Person who has given consent to participate in the study * Person agreeing to the recording of the semi-directive interview * Person of legal age Ancillary study : * Eligible patient who has given consent to participate in the APIS study * Patient agreeing to participate in the ancillary study (box checked on the APIS informed consent form) Exclusion Criteria: For all patients: * Person deprived of liberty by judicial or administrative decision * Person under psychiatric care (unstable pathology) * Person of full age under legal protection (guardianship, curatorship) * Person unable to receive sufficient information due to impaired higher functions, or insufficient command of the French language * Person participating in another interventional research study with an exclusion period still in progress at the time of pre-inclusion * Person with absolute contraindications to physical exercise: * Unstable angina * Decompensated heart failure * Complex ventricular rhythm disorders * Uncontrolled severe arterial hypertension * Pulmonary arterial hypertension (\> 60 mm Hg) * Presence of large or pedunculated intracavitary thrombus * Acute pericardial effusion * Severe obstructive cardiomyopathy * Tight and/or symptomatic aortic stenosis * Recent thrombophlebitis with or without pulmonary embolism * Diabetes with plantar perforator disease for physical activity activities involving the lower limbs * Persons with musculoskeletal pathologies making cycling impossible

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Service de Chirurgie Gynécologie-Obstétrique,CHU Hôpital Nord

    NOT_YET_RECRUITING

    Saint-Priest-en-Jarez, 42270, France

  • Service de Gynécologie-Obstétrique, Groupement Hospitalier Nord, Hospices Civils de Lyon

    RECRUITING

    Lyon, 69317, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.